Diversify Wealth Management LLC grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% during the ...

Ameritas Advisory Services LLC increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 25.9% during the fourth quarter, according to the company in its most recent disclosure ...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary artery disease (CAD).

May 2017 – Outcomes-based agreements with AstraZeneca for Brilinta (ticagrelor) and Bydurean (exenatide extended-release) to treat acute coronary disease and type II diabetes respectively.

A new investigation published by The BMJ highlights fresh concerns about the PLATO clinical trial, a pivotal study that led to the global approval of the anti-platelet drug ticagrelor (marketed as ...

ABU DHABI, 6th June, 2017 (WAM) -- The UAE Ministry of Health and Prevention has issued a circular to all medical facilities and hospitals to withdraw Brilinta 90 mg batch number JB504 by AstraZeneca, ...

kabaddi cup 2024 AstraZeneca's Brilinta approved to reduce risk of first heart attack or stroke in CAD The 2020 China Big Health Industry Summit will be held in Guangzhou in September with many ...

AstraZeneca (NASDAQ:AZN) is one of the biggest players in the healthcare sector, whose medicines save the lives of tens of thousands of people every year. In this article, I will share six reasons ...

AstraZeneca still trades at a premium valuation, but several factors limit its upside potential in the next visible period. There are three negative takeaways from China. IRA could also ...

Jan 17 (Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca (AZN.L), opens new tab and partner Daiichi Sankyo's (4568.T), opens new tab precision drug to treat a type of ...